AstraZeneca (NASDAQ:AZN) is one of the best future stocks to buy for the long term. On January 6, Barclays analyst James Gordon raised the firm’s price target on AstraZeneca to 16,500 GBp from 14,000 GBp, while maintaining an Overweight rating on the shares. On the same day, AstraZeneca (NASDAQ:AZN) also published positive full results from the Phase III TULIP-SC trial, confirming that the subcutaneous/SC administration of Saphnelo (anifrolumab) significantly reduces disease activity in patients with syst ...